Measles, mumps, rubella, and varicella virus vaccine live Subcutaneous and Sitagliptin Phosphate

• Generic Name: measles virus vaccine / mumps virus vaccine / rubella virus vaccine / varicella virus vaccine
• Dosage Forms: n.a.
• Other Brand Names: ProQuad

Measles, mumps, rubella, and varicella virus vaccine (live) is an active immunizing agent that is given to protect against infections caused by measles (rubeola), mumps, rubella (German measles), and varicella (chickenpox) viruses. The combination vaccine works by causing the body to produce its own protection (antibodies) against these diseases.

Measles (also known as coughing measles, hard measles, morbilli, red measles, rubeola, and 10-day measles) is an infection that is easily spread from one person to another. Infection with measles can cause serious problems, such as stomach problems, pneumonia, ear infections, sinus problems, convulsions (seizures), brain damage, and possibly death. The risk of serious complications and death is greater for adults and infants than for children and teenagers.

Mumps is an infection that can cause serious problems, such as encephalitis and meningitis, which affect the brain. In addition, teenage boys and men are very susceptible to a condition, called orchitis, which causes pain and swelling in the testicles and scrotum, and in rare cases, sterility. Also, mumps infection can cause spontaneous abortion (miscarriage) in women during the first 3 months of pregnancy.

Rubella (also known as German measles) is a serious infection that causes miscarriages, stillbirths, or birth defects in unborn babies when pregnant women get the disease.

Varicella (commonly known as chickenpox) is an infection that is easily spread from one person to another. Chickenpox is usually a mild infection but can sometimes cause serious problems, such as pneumonia, inflammation of the brain, and a rare disease, called Reye's syndrome.

Immunization against measles, mumps, german measles, and chickenpox is recommended for children 12 months to 12 years of age who have not had these diseases. Immunization against these diseases is not recommended for infants younger than 12 months of age and for children 13 years of age and older.

This vaccine is to be administered only by or under the supervision of your child’s doctor or other authorized healthcare professional.

• Generic Name: sitagliptin
• Dosage Forms: n.a.
• Other Brand Names: Januvia

Used as monotherapy as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.

Used in combination with immediate- or extended-release metformin given separately or as a fixed combination (Janumet or Janumet XR, respectively) as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus when treatment with both sitagliptin and metformin is appropriate.

Used in fixed combination with ertugliflozin (Steglujan) as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus when treatment with both drugs is appropriate.

Used in combination with other oral antidiabetic agents (e.g., metformin, a sulfonylurea, a thiazolidinedione [peroxisome proliferator-activated receptor-γ agonist]) or insulin as an adjunct to diet and exercise in patients with type 2 diabetes mellitus who have not achieved adequate glycemic control with one or more oral antidiabetic agents and/or insulin.

American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) suggests a DPP-4 inhibitor as one of several alternatives for initial monotherapy in patients with metformin contraindications (e.g., renal disease, hepatic disease, GI intolerance, risk of lactic acidosis). DPP-4 inhibitors also recommended as part of combination therapy, particularly with both postprandial and fasting plasma glucose elevations.

Not indicated for use in patients with type 1 diabetes mellitus or diabetic ketoacidosis; insulin is required in these conditions.